AvevoRx Signs Agreement for Subcutaneous Immunoglobulin Drug CUVITRU®

averorx circle

Deal announced amidst continuous, rapid growth and expansion for AvevoRx 

Greensboro, N.C. – September 14, 2023 – AvevoRx, a national, independent provider of specialty infusion pharmacy services, has signed an agreement with Cambridge, Mass.-based Takeda (TSE:4502/NYSE: TAK) to offer its subcutaneous immunoglobulin (Ig) drug CUVITRU to patients under its care. The signing is a notable milestone for AvevoRx during a year of continuous, rapid growth and expansion. 

AvevoRX was founded in 2022 and has seen rapid growth and expansion of its geographic footprint and therapy portfolio in that time.   The addition of CUVITRU to its drug portfolio allows the company to deliver a more robust clinical and therapy offering to Immunologists and patients in the immune deficiency community.

“Being able to offer patients with increasingly diverse treatment needs the widest range of drug therapy options possible, has been a focus of our development and expansion,” said Eric Hill, co-founder of AvevoRx. “This latest deal with Takeda allows us to further deliver on that goal. It’s a testament to the clinical and management programs our teams have built and continue to refine.” 

Added Justin Dent, national director of pharmacy operations for AvevoRx, “Adding CUVITRU to our portfolio of treatment options helps address the needs of a patient population that requires or benefits from receiving treatments subcutaneously. Meeting and supporting patients where they are, to maximize their comfort, safety, and effectiveness, remain our top priorities.” 

Visit AvevoRx.com for more information. 

About AvevoRx

AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit www.AvevoRx.com or follow us on Instagram or LinkedIn.


About AvevoRX

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.

Enter your phone number for a call back from our staff​

Getting started is easy.

For more information please contact us using the form or give us a call.

number one
To refer a patient, call (877) 283-8679
number 2
Fax your referral to (800) 987-6552
number 3
Click Here and enter your phone number for a call back from our staff